PL1753398T3 - Macierz o kontrolowanym uwalnianiu farmaceutycznej formulacji dawkowania - Google Patents

Macierz o kontrolowanym uwalnianiu farmaceutycznej formulacji dawkowania

Info

Publication number
PL1753398T3
PL1753398T3 PL05759882T PL05759882T PL1753398T3 PL 1753398 T3 PL1753398 T3 PL 1753398T3 PL 05759882 T PL05759882 T PL 05759882T PL 05759882 T PL05759882 T PL 05759882T PL 1753398 T3 PL1753398 T3 PL 1753398T3
Authority
PL
Poland
Prior art keywords
dosing
matrix
controlled release
pharmaceutical formulation
formulation
Prior art date
Application number
PL05759882T
Other languages
English (en)
Inventor
Orapin P. Rubino
David M. Jones
Original Assignee
Glatt Air Techniques Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glatt Air Techniques Inc filed Critical Glatt Air Techniques Inc
Publication of PL1753398T3 publication Critical patent/PL1753398T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL05759882T 2004-06-10 2005-06-08 Macierz o kontrolowanym uwalnianiu farmaceutycznej formulacji dawkowania PL1753398T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57893004P 2004-06-10 2004-06-10
EP05759882.3A EP1753398B1 (en) 2004-06-10 2005-06-08 Controlled release matrix pharmaceutical dosage formulation
PCT/US2005/020203 WO2005123045A2 (en) 2004-06-10 2005-06-08 Controlled release matrix pharmaceutical dosage formulation

Publications (1)

Publication Number Publication Date
PL1753398T3 true PL1753398T3 (pl) 2019-04-30

Family

ID=35510245

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05759882T PL1753398T3 (pl) 2004-06-10 2005-06-08 Macierz o kontrolowanym uwalnianiu farmaceutycznej formulacji dawkowania

Country Status (9)

Country Link
US (2) US20070212416A1 (pl)
EP (1) EP1753398B1 (pl)
JP (2) JP2008502727A (pl)
CN (1) CN1988884B (pl)
CA (1) CA2569968C (pl)
ES (1) ES2702608T3 (pl)
PL (1) PL1753398T3 (pl)
TR (1) TR201819108T4 (pl)
WO (1) WO2005123045A2 (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100753480B1 (ko) * 2006-01-27 2007-08-31 씨제이 주식회사 잘토프로펜 함유 서방성 정제 및 그 제조방법
JP2007308480A (ja) * 2006-04-20 2007-11-29 Shin Etsu Chem Co Ltd 腸溶性固体分散体を含んでなる固形製剤
CA2672602C (en) 2006-12-18 2014-05-20 Electronic Dietary Foods Inc. Device for delivery of a substance
RU2571067C2 (ru) * 2009-01-22 2015-12-20 Эбботт Хелткеа Прайвит Лимитед Хронотерапевтическая фармацевтическая композиция
IL210279A0 (en) 2009-12-25 2011-03-31 Dexcel Pharma Technologies Ltd Extended release compositions for high solubility, high permeability acdtive pharmaceutical ingredients
CN102000338B (zh) * 2010-11-19 2012-09-05 黄旻 一种二氧化硅小丸及制备方法
WO2015198304A1 (en) 2014-06-22 2015-12-30 Dexcel Pharma Technologies Ltd. Pharmaceutical compositions comprising ferric citrate and methods for the production thereof
CA3001495C (en) * 2014-11-03 2021-07-20 Solipharma Llc Formulations of dabigatran etexilate or dabigatran etexilate salts and preparation methods thereof
US9980946B1 (en) * 2017-01-25 2018-05-29 Effcon Laboratories, Inc. Extended release methazolamide formulation
JP7132947B2 (ja) * 2017-05-02 2022-09-07 ルブリゾル アドバンスド マテリアルズ， インコーポレイテッド 改善された持続放出性高充填薬物組成物
JP2025536556A (ja) 2022-10-25 2025-11-07 ヴェラダーミクス インコーポレイテッド 放出調節ミノキシジル用組成物および使用方法
US20250345330A1 (en) * 2024-04-24 2025-11-13 Veradermics, Incorporated Compositions and methods of use for modified release minoxidil

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61148115A (ja) * 1984-12-21 1986-07-05 Tooa Eiyoo Kk 難溶性薬物の徐放性製剤及びその製造法
CA1259924A (en) * 1985-03-25 1989-09-26 Wallace E. Becker Pharmaceutical tableting method
GB8628359D0 (en) * 1986-11-27 1986-12-31 Zyma Sa Galenical formulation
JP2969345B2 (ja) * 1987-01-29 1999-11-02 武田薬品工業株式会社 有核顆粒およびその製造法
JPS6471822A (en) * 1987-09-12 1989-03-16 Rohto Pharma Ophthalmic sustained release preparation
JP2718957B2 (ja) * 1988-10-05 1998-02-25 ポリプラスチックス株式会社 結晶性熱可塑性樹脂成形品の静電塗装方法並びに塗装プラスチックス成形品
US4925676A (en) * 1989-02-02 1990-05-15 Warner-Lambert Company Extended release gemfibrozil composition
US4927639A (en) * 1989-02-02 1990-05-22 Warner-Lambert Company Modified release gemfibrozil composition
US5007790A (en) * 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US5260073A (en) * 1990-05-21 1993-11-09 Norwich Eaton Pharmaceuticals, Inc. Use of phenylpropanolamine as a mucus secretogogue in the upper airways
BE1009257A3 (nl) * 1995-03-21 1997-01-07 Universiteit Gent Lab Voor Far Farmaceutische matrix.
US5811126A (en) * 1995-10-02 1998-09-22 Euro-Celtique, S.A. Controlled release matrix for pharmaceuticals
JP3693270B2 (ja) * 1995-10-12 2005-09-07 旭化成ケミカルズ株式会社 フィルムコーティング顆粒およびその製造方法
JPH09295947A (ja) * 1996-04-30 1997-11-18 Nippon Paper Ind Co Ltd 微小球形粒及びその製造方法
US6361794B1 (en) * 1996-06-12 2002-03-26 Basf Corporation Method of making ibuprofen and narcotic analgesic composition
WO2000018500A1 (de) * 1998-09-24 2000-04-06 Glatt Systemtechnik Dresden Gmbh Einrichtung zur herstellung eines schüttfähigen produktes und verfahren zur anwendung der einrichtung
US6607751B1 (en) * 1997-10-10 2003-08-19 Intellipharamaceutics Corp. Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum
US6337091B1 (en) * 1997-10-27 2002-01-08 Temple University - Of The Commonwealth System Of Higher Education Matrix for controlled delivery of highly soluble pharmaceutical agents
US20030059471A1 (en) * 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
JP2002505269A (ja) * 1998-03-06 2002-02-19 エウランド インターナショナル ソシエタ ペル アチオニ 急速崩壊錠剤
AP1224A (en) * 1998-03-19 2003-11-14 Bristol Myers Squibb Co Biphasic controlled release delivery system for high solubility pharmaceuticals and method.
US6110500A (en) * 1998-03-25 2000-08-29 Temple University Coated tablet with long term parabolic and zero-order release kinetics
JP4711472B2 (ja) * 1998-10-20 2011-06-29 旭化成ケミカルズ株式会社 フィルムコーティング顆粒
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
FR2796840B1 (fr) * 1999-07-26 2003-06-20 Ethypharm Lab Prod Ethiques Comprimes faiblement doses et procede de preparation
WO2003024427A1 (en) * 1999-12-20 2003-03-27 Temple University Of The Commonwealth System Of Higher Education Tableted oral extended release dosage form
JP4493769B2 (ja) * 1999-12-21 2010-06-30 旭化成ケミカルズ株式会社 球形顆粒
EP1280533A2 (en) * 2000-05-11 2003-02-05 Pharmacia Corporation Aldosterone antagonist composition for release during aldosterone acrophase
AU2002221412B2 (en) * 2000-12-05 2006-04-13 Alexander Macgregor Hydrostatic delivery system for controlled delivery of agent
JP4438268B2 (ja) * 2001-03-07 2010-03-24 大日本住友製薬株式会社 薬物顆粒の製造方法、および薬物顆粒、ならびにそれを用いた医薬製剤
EA005537B1 (ru) * 2001-07-10 2005-04-28 Тева Фармасьютикал Индастриес Лтд. Система доставки лекарственного вещества по нулевому порядку, нулевому порядку - двухстадийной, возрастающей или убывающей доставки препарата
PL361452A1 (pl) * 2001-07-27 2004-10-04 Yamanouchi Pharmaceutical Co.Ltd. Kompozycja zawierająca drobne cząstki o spowolnionym uwalnianiu przeznaczona do zastosowania w tabletkach szybko rozpadających się w przedsionku jamyustnej, oraz sposób ich wytwarzania
US20030133982A1 (en) * 2001-12-20 2003-07-17 Heimlich John M. Zero-order sustained release dosage forms and method of making same
KR100540035B1 (ko) * 2002-02-01 2005-12-29 주식회사 태평양 다단계 경구 약물 방출 제어 시스템
CO5400144A1 (es) * 2002-03-11 2004-05-31 Novartis Ag Compuestos organicos
US20030219482A1 (en) * 2002-03-21 2003-11-27 Chaudhari Sunil Sudhakar Multiparticulate compositions for once-a-day administration
DE10224170A1 (de) * 2002-05-31 2003-12-11 Desitin Arzneimittel Gmbh Pharmazeutische Zusammensetzung mit verzögerter Wirkstofffreisetzung
US9107804B2 (en) * 2002-12-10 2015-08-18 Nortec Development Associates, Inc. Method of preparing biologically active formulations
EP1590144B1 (en) * 2002-12-10 2015-07-29 Nortec Development Associates, Inc. Method of preparing biologically active formulations
CN1212840C (zh) * 2003-01-08 2005-08-03 江苏正大天晴药业股份有限公司 苦参素缓释制剂及其制备方法
CA2566311A1 (en) * 2004-05-19 2005-12-08 Glatt Air Techniques, Inc. Micropellet containing pellets and method of preparing such pellets

Also Published As

Publication number Publication date
EP1753398A2 (en) 2007-02-21
CA2569968C (en) 2014-08-19
WO2005123045A3 (en) 2006-03-02
EP1753398B1 (en) 2018-09-19
CN1988884A (zh) 2007-06-27
ES2702608T3 (es) 2019-03-04
US20070212416A1 (en) 2007-09-13
JP2008502727A (ja) 2008-01-31
EP1753398A4 (en) 2008-09-17
WO2005123045A2 (en) 2005-12-29
US9687451B2 (en) 2017-06-27
TR201819108T4 (tr) 2019-01-21
CN1988884B (zh) 2013-01-02
US20100255090A1 (en) 2010-10-07
JP2013216711A (ja) 2013-10-24
CA2569968A1 (en) 2005-12-29

Similar Documents

Publication Publication Date Title
DK1830907T3 (da) Hætte til lægemiddelfrigivelsesanordninger
DK1962932T3 (da) Indretning til medikamentdosering
DK2073795T3 (da) Misbrugssikret lægemiddelformulation
ATE551989T1 (de) Kleinmolekülige heilmittelformulierung mit verzögerter freisetzung
DK2058020T3 (da) Indretning til indgivelse af lægemiddel
ITBO20050123A1 (it) Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
MA28489B1 (fr) Preparations pharmaceutiques
NO20075628L (no) Farmasøytiske formuleringer
FR2881652B1 (fr) Forme pharmaceutique orale microparticulaire anti-mesuage
SK4070U (sk) Farmaceutická kompozícia na riadené uvoľňovanie účinných látok
DK1983964T3 (da) Anordning til indgivelse af lægemiddel
FR2892937B1 (fr) Forme pharmaceutique orale microparticulaire anti-mesusage
BRPI0821115A2 (pt) Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto
SK4325U (sk) Farmaceutická kompozícia s postupným uvoľňovaním
DK3072507T3 (da) Farmaceutiske sammensætninger til glukokortikoidsubstitutionsterapi
PL1753398T3 (pl) Macierz o kontrolowanym uwalnianiu farmaceutycznej formulacji dawkowania
BRPI0615135A2 (pt) composições de fármacos contendo matrizes de hipromelose de liberação controlada
EP1753405A4 (en) SLOW RELEASE PHARMACEUTICAL PREPARATION
DK2918286T3 (da) En farmaceutisk formulering
IS7383A (is) Skammtaform með stýrða lyflosun til inngjafar
IS7290A (is) Lyfjasamsetningar sem innihalda risperidone
ITMI20041447A1 (it) Composizione farmaceutica comprendente gabapentina
ITMI20040943A1 (it) Composizione farmaceutica cicatrizzante
DE602005007319D1 (de) Zubereitung zur kontinuierlichen Arzneimittelfreisetzung Chitosan enthaltend
EP1747205A4 (en) PHARMACEUTICAL COMPOSITIONS